Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Japan Biologics Business Strategies

Anaeropharma Co-Opts Microbe For Targeted Fight Against Hypoxic Tumors

Executive Summary

Japanese venture Anaeropharma Science is working on a unique approach to targeted drug delivery it says confers advantages including fewer systemic side effects, and the technology is already seeing validation through several research deals with major Japanese pharma companies.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.

Table

View full table

Topics

Related Companies

Tags:
Japan Biologics Business Strategies
Latest Headlines

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

SC124225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By